Since these TB-IRIS patients were recruited under similar clinical conditions as HIV+TB+ controls (i.e. similar CD4 counts and treatment interval), one could argue that a diminished activation of phagocytotic cells such as neutrophils and macrophages would slow down the clearance of TB-bacilli and their antigens in the window between TB-treatment and ART. This evidence concerns the gene CD4 and tuberculosis.